Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Rachel Mcminn Insider Profile

18 Followers

Rachel Mcminn, CEO, Director at Neurogene, holds 1.35M shares in Neurogene (Ticker: NGNE), holds 7.62K shares in Intercept Pharma (Ticker: ICPT).

Rachel Mcminn's Trading History

NGNENeurogene		Oct 02, 2026CEO, DirectorUninformative Buy19.14K$37.06M
ICPTIntercept Pharma		Oct 04, 2017―Informative Sell16.67K$144.80K
See All Insider Trading from Today

You May Also Like

Meet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.

Rachel Mcminn insider profile FAQ

What is the percentage of profitable transactions made by Rachel Mcminn?
The percentage of profitable transactions made by Rachel Mcminn is 78%.
What is the average return per transaction made by Rachel Mcminn?
The average return per transaction made by Rachel Mcminn is 18.70%.
What stocks does Rachel Mcminn hold?
Rachel Mcminn holds: NGNE, ICPT stocks.
What was Rachel Mcminn’s latest transaction?
Rachel Mcminn’s latest transaction was an Uninformative Buy of $19.14K.
What was Rachel Mcminn's most profitable transaction?
Rachel Mcminn’s most profitable transaction was an Informative Sell of ICPT stock on November 4, 2015. The return on the trade was 47.00%.
What is Rachel Mcminn's role in Neurogene?
Rachel Mcminn's role in Neurogene is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.